Genexine Voluntarily Withdraws COVID-19 Preventive Vaccine Clinical Trial
[Asia Economy Reporter Lee Seon-ae] Genexine announced on the 11th that it will voluntarily withdraw the Phase 2/3 clinical trial of the COVID-19 preventive vaccine ‘GX-19N’.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- NVIDIA Reports $81.6 Billion in Q1 Revenue, Sets Record for 12 Consecutive Quarters (Comprehensive)
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Genexine stated, “As the primary vaccination and booster shots in Indonesia have rapidly expanded to the entire population, the clinical trial environment has changed,” adding, “It has become difficult to recruit and manage clinical trial participants, including the placebo group, and ethical issues may arise. Therefore, we voluntarily withdraw the approval for the clinical trial plan targeting unvaccinated individuals and the amendment application for the booster clinical trial plan targeting vaccinated individuals.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
